筛查人群中Prostagram磁共振成像:前列腺影像报告和数据系统还是Likert评分?
在50-69岁男性筛查人群中比较PI-RADSv2与Likert量表对Prostagram MRI的活检推荐率和诊断准确性。Likert量表在评分≥3时推荐更多活检(23% vs 18%,P=0.03),但两组对临床显著癌(GG≥2)和GG1的检出率无显著差异,ROC曲线下面积相似(0.64 vs 0.65,P=0.95)。
要点
- 在筛查人群中,PI-RADSv2与Likert量表对Prostagram MRI的准确性相似(AUC 0.64 vs 0.65,P=0.95)。
- Likert量表在评分≥3时推荐更多男性进行活检(23% vs 18%,P=0.03),但未增加显著癌检出率。
- 作者建议开发PI-RADSv2、改良Likert量表或独立评分系统以改进Prostagram MRI的报告。
核心结论
- 在筛查人群中报告非增强Prostagram MRI时,PI-RADSv2和Likert评分系统准确性相同;但使用Likert量表导致更多男性接受活检,而未相应增加显著癌检出率。
研究设计与样本
- 在Imperial Prostate 1前列腺癌筛查试验(IP1-PROSTAGRAM)中,50-69岁男性接受Prostagram MRI筛查,由专家泌尿放射科医生前瞻性使用PI-RADSv2(排除动态对比增强序列评分)和5点Likert评分同时报告。
- 若任一评分系统评分≥3,则推荐进行系统穿刺和靶向经会阴穿刺活检。
- 共406名男性接受了Prostagram MRI,中位(四分位距)年龄为57(53-61)岁,前列腺特异性抗原水平为0.91(0.56-1.74)ng/mL。
主要发现
- 在MRI评分≥3时,基于Likert标准推荐活检的患者为94/406(23%,95%CI 19.2%-27.6%),基于PI-RADSv2为72/406(18%,95%CI 14.2%-21.9%;P=0.03)。
- 在MRI评分≥4时,PI-RADSv2和Likert量表分别推荐43/406(11%,95%CI 7.9%-14.1%)和35/406(9%,95%CI 6.2%-11.9%)名男性进行活检(P=0.40)。
- 对于GG≥2检出,PI-RADSv2和Likert分别检出22%(95%CI 11.4%-30.8%,14/72)和16%(95%CI 9.5%-25.3%,15/94)(P=0.56)。
- 对于GG1癌检出,PI-RADSv2和Likert分别为11%(95%CI 4.3%-19.6%,7/72)和11%(95%CI 4.7%-17.8%,9/94;P=1.00)。
- PI-RADSv2和Likert量表的准确性相似(ROC曲线下面积0.64 vs 0.65,P=0.95)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare biopsy recommendation rates and accuracy of the Prostate Imaging-Reporting and Data System, version 2 (PI-RADSv2) with the Likert scale for detection of clinically significant and insignificant prostate cancer in men screened within the Imperial Prostate 1 Prostate Cancer Screening Trial Using Imaging (IP1-PROSTAGRAM). PATIENTS AND METHODS: Men aged 50-69 years were screened with Prostagram MRI. Scans were prospectively reported using both PI-RADSv2 (excluding dynamic contrast-enhanced sequence score) and 5-point Likert scores by expert uro-radiologists. Systematic and targeted transperineal biopsy was recommended if the scan was scored ≥ 3, based on either reporting system. The proportion of patients recommended for biopsy and detection rates for Grade Groups (GGs) 1 and ≥ 2 were compared. Receiver operating characteristic (ROC) analysis was performed to compare performance. RESULTS: A total of 406 men underwent Prostagram MRI. The median (interquartile range) age and prostate-specific antigen level were 57 (53-61) years and 0.91 (0.56-1.74) ng/mL, respectively. At MRI score ≥ 3, more patients were recommended for biopsy based on Likert criteria (94/406; 23%, 95% confidence interval [CI] 19.2%-27.6%) compared to PI-RADSv2 (72/406; 18%, 95% CI 14.2%-21.9%; P = 0.03). For MRI scores ≥ 4, PI-RADSv2 and Likert scales led to 43/406 (11%, 95% CI 7.9%-14.1%) and 35/406 (9%, 95% CI 6.2%-11.9%) men recommended for biopsy (P = 0.40). For GG ≥ 2 detection, PIRADSv2 and Likert detected 22% (95% CI 11.4%-30.8%, 14/72) and 16% (95% CI 9.5%-25.3%, 15/94), respectively (P = 0.56). For GG1 cancers detection these were 11% (95% CI 4.3%-19.6%, seven of 72) vs 11% (95% CI 4.7%-17.8%, nine of 94; P = 1.00). The accuracy of PI-RADSv2 and Likert scale was similar (area under the ROC curve 0.64 vs 0.65, P = 0.95). CONCLUSIONS: In reporting non-contrast-enhanced Prostagram MRI in a screening population, the PI-RADSv2 and Likert scoring systems were equally accurate; however, Likert scale use led to more men undergoing biopsy without a subsequent increase in significant cancer detection rates. To improve reporting of Prostagram MRI, either the PI-RADSv2 or a modified Likert scale or a standalone scoring system should be developed.
引用
- Mayor N, Eldred-Evans D, Tam H, et al. Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert? BJU Int. 2023. PMID: 37591614. doi:10.1111/bju.16155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。